# Oculis Holding AG > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/fi/companies/Oculis Holding AG). ## Overview Oculis Holding AG is a Switzerland-based biopharmaceutical company focused on therapies for neuro-ophthalmology and ophthalmology. Its business centers on developing late-stage ophthalmic and neuroprotective product candidates through its group of wholly owned subsidiaries, with operations in Switzerland, the United States, and Iceland. ## Products & services • OCS-01 ophthalmic eye drop for diabetic macular edema • Privosegtor neuroprotective candidate for optic neuropathies • Licaminlimab topical anti-TNFα for dry eye disease • Late-stage clinical development programs • Precision-medicine ophthalmology research and registration support - **OCS-01** (0%) — Ophthalmic eye-drop candidate developed for retinal disease, including diabetic macular edema. - **Licaminlimab** (0%) — Topical anti-TNFα candidate being developed for dry eye disease using a genotype-based approach. - **Privosegtor** (0%) — Neuroprotective candidate aimed at optic neuropathies such as optic neuritis and NAION. - **Clinical development services** (100%) — Internal research, trial execution, and regulatory-enabling development for the pipeline. - OCS-01 ophthalmic eye drop for diabetic macular edema - Privosegtor neuroprotective candidate for optic neuropathies - Licaminlimab topical anti-TNFα for dry eye disease - Late-stage clinical development programs - Precision-medicine ophthalmology research and registration support ## Customers Oculis does not sell a commercial product portfolio; its main counterparties are patients, clinicians, investigators, regulators, and future commercial partners in ophthalmology and neurology. The company’s pipeline is designed for diseases with unmet medical need, so adoption would depend on ophthalmologists, retina specialists, and neuro-ophthalmology specialists if approved. Current economic value is driven by development progress rather than repeat product sales. - **Patients with eye and optic nerve disease** (primary) — Potential end users of OCS-01, Licaminlimab, and Privosegtor for retinal, dry eye, and optic neuropathy indications. - **Ophthalmology specialists** (primary) — Physicians who would prescribe or administer approved therapies for diabetic macular edema and dry eye disease. - **Clinical investigators and trial centers** (primary) — Hospitals, clinics, and investigators that enroll patients and generate registrational data. - **Regulatory authorities** (secondary) — FDA and other agencies that review trial evidence and determine registration pathways. - **Potential strategic partners** (secondary) — Pharma or biotech partners that may license, co-develop, or commercialize pipeline assets. - Patients with diabetic macular edema, dry eye disease, and optic neuropathies - Ophthalmologists and retina specialists evaluating future adoption - Neuro-ophthalmology specialists for optic nerve disease programs - Clinical trial sites and investigators running registrational studies - Regulators and potential licensing partners for development milestones ## Geography Oculis is headquartered in Zug, Switzerland, and describes operations in Switzerland, the United States, and Iceland. Its development programs are global in scope because clinical trials, regulatory work, and future commercialization in ophthalmology typically span multiple geographies. - Headquartered in Zug, Switzerland - Operations in the United States, Iceland, and Switzerland - Clinical development is global rather than single-market - Future commercialization would depend on major ophthalmic markets - Multi-country footprint supports research, trials, and regulatory work ## Strategy Oculis’ strategy is centered on advancing a late-stage ophthalmology and neuro-ophthalmology pipeline with differentiated mechanisms of action. The company emphasizes registrational development, precision-medicine positioning in dry eye disease, and neuroprotection for optic nerve disorders to create high-value clinical proof points. - **Progress registrational trials for pipeline assets** (short-term) — Late-stage clinical readouts are the main value-creation events for a development-stage biotech. - **Build evidence for precision-medicine positioning** (medium-term) — Genotype-based patient selection can improve differentiation in dry eye disease. - **Expand indications beyond initial targets** (medium-term) — Broader label potential can increase commercial opportunity and pipeline resilience. - Advance late-stage programs toward registration - Position Licaminlimab as a precision-medicine dry eye therapy - Develop Privosegtor for optic neuritis and NAION - Maintain optionality across ophthalmology and neuro-ophthalmology - Use clinical data to support partnering and future commercialization ## Risks As a clinical-stage biopharma company, Oculis faces material binary trial, regulatory, and development risks, with value heavily dependent on successful endpoints and approval pathways. Its business also depends on protecting and validating licensed assets, while funding needs remain tied to long development cycles and uncertain commercialization timing. - **Clinical development failure** [critical] — The company’s value depends on achieving positive outcomes in late-stage trials for OCS-01, Licaminlimab, and Privosegtor. - **Regulatory approval risk** [high] — Even successful trials may not translate into approval if the evidence package or indication strategy is insufficient. - **License impairment risk** [high] — Management explicitly tests key licenses for impairment based on fair value and continued development feasibility. - **Financing and dilution risk** [high] — Pre-revenue biotech programs require ongoing capital for trials, regulatory work, and operations. - **Specialty market adoption risk** [medium] — Commercial uptake, if approved, depends on physician acceptance in narrow ophthalmology and neuro-ophthalmology niches. - Clinical trial failure could eliminate or delay key pipeline value - Regulatory outcomes are uncertain for each registrational program - Asset impairment risk exists if licenses lose development viability - Funding needs are high because revenue is pre-commercial - Specialist drug development carries execution and enrollment risk ## Accounting The key accounting issues for Oculis are valuation and impairment judgments for in-process licenses, especially where outcomes depend on clinical feasibility and market-based fair value assumptions. Because the company is development-stage and pre-commercial, share-based compensation, tax-loss recognition, and foreign-currency translation also have a meaningful effect on reported results. - **License impairment** — Could trigger non-cash write-downs - **Deferred tax assets** — Affects balance sheet and equity - **Share-based compensation** — Raises operating expense and loss - **Foreign currency translation** — Creates comprehensive income volatility - Impairment testing for licensed product candidates - Fair value modeling for company-level and asset-level assessments - Deferred tax asset recognition on accumulated tax losses - Share-based compensation affects operating expenses - Foreign currency translation affects comprehensive income --- *Last updated: 2026-09-28T12:13:31.808037+00:00*